Immediate Post-placental Insertion of IUCD During Cesarean Delivery Versus 6 Week Post-Cesarean Insertion
Launched by ALSHAIMAA ABOALHASSAN ALI · Jan 18, 2018
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
Intrauterine devices (IUDs) are among the most effective forms of contraception, offering greater than 99% efficacy per year of use and are completely reversible .
Post-placental intrauterine device (IUD) insertion is a safe, convenient, and effective option for postpartum contraception. "Post-placental" refers to insertion within 10-15 minutes of placental delivery, after vaginal or cesarean delivery.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age: 18 -45
- • Singleton pregnancy at ≥32 weeks gestation at time of enrollment
- • Voluntarily requesting to IUD placement for postpartum contraception
- • Able to give consent and agree to the terms of the study
- Exclusion Criteria:
- • 1. Uterine anomaly that preventing replacement of IUD.
- • 2. Chorioamnionitis (such as prolonged rupture of membranes \>18 hours, prolonged labor \>24 hours, fever \>38C).
- • 3. Puerperal sepsis and unresolved postpartum hemorrhage.
- • 4. IUD allergy (copper).
- • 5. Systemic lupus erythematosus with severe thrombocytopenia
About Alshaimaa Aboalhassan Ali
Alshaimaa Aboalhassan Ali is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a strong focus on ethical standards and regulatory compliance, she leads innovative studies aimed at evaluating new therapies and interventions across various therapeutic areas. Alshaimaa's expertise encompasses the design, implementation, and oversight of clinical trials, ensuring rigorous methodologies and data integrity. Her collaborative approach fosters partnerships with healthcare professionals and research institutions, driving forward the development of effective treatment options for patients in need.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, Ain Shams, Egypt
Patients applied
Trial Officials
Yasser M Aboutalib, MD
Study Director
Ain Shams University
Ahmed S AbdelHamid, MD
Study Director
Ain Shams University
ALshaimaa A Ali, MBBch
Principal Investigator
Ain Shams University
Haitham Torky, MD
Study Director
Ain Shams University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials